Please login to the form below

Not currently logged in
Email:
Password:

Dupixent

This page shows the latest Dupixent news and features for those working in and with pharma, biotech and healthcare.

Sanofi and Regeneron announce positive phase 3 trial results for eosinophilic oesophagi in children under 12

Sanofi and Regeneron announce positive phase 3 trial results for eosinophilic oesophagi in children under 12

At 16 weeks, 68% of children on the higher dose, and 58% on the lower dose of Dupixent ‘achieved the primary endpoint of significant histological disease remission’. ... Dupixent is a fully human monoclonal antibody that inhibits the signalling of

Latest news

More from news
Approximately 28 fully matching, plus 34 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...